Tahereh Yavari: 2025 EULAR Update – Redefining Lupus Nephritis Management
Tahereh Yavari, Assistant professor of internal medicine at Tehran University of Medical Sciences (TUMS), shared a post on LinkedIn:
“2025 EULAR Update: Redefining Lupus Nephritis Management
The European Alliance of Associations for Rheumatology (EULAR) has just released its 2025 recommendations for the management of Systemic Lupus Erythematosus (SLE) with kidney involvement, led by Antonis Fanouriakis et al.
This update reflects a paradigm shift in how we approach lupus nephritis (LN) — integrating precision immunotherapy, treat-to-target, and shared decision-making principles.
⸻
What’s New in the 2025 EULAR Guidance
1. Early, biopsy-based stratification:
Renal biopsy remains central — guiding both class-specific and activity/chronicity-driven treatment decisions. Repeat biopsy is encouraged in relapsing or refractory disease.
2. Triple therapy endorsed for active Class III/IV ± V LN:
• Glucocorticoid (low-dose, rapidly tapered)
• Mycophenolate mofetil or low-dose IV cyclophosphamide
• Add-on biologic: belimumab or voclosporin recommended as part of the initial regimen.
3. Maintenance therapy evolution:
Tacrolimus, azathioprine, or mycophenolate remain standards — but now, biologic continuation (esp. belimumab) is acceptable for sustained control and flare prevention.
4. Treatment goals:
Aim for proteinuria < 0.5 g/day and eGFR stabilization by 12 months — consistent with EULAR’s treat-to-target philosophy.
5. Beyond immunosuppression:
Multidisciplinary care, BP control (ACEi/ARB first-line), lipid and bone health, and pregnancy-safe planning are emphasized as equal pillars of LN care.
⸻
Clinical Takeaway
Lupus nephritis management is entering an era of combination precision therapy —
- Early targeted immunomodulation instead of stepwise escalation,
- Less steroid exposure,
- Integration of biologics from the start, and
- Continuous renal and serologic monitoring toward individualized remission.
⸻
Fanouriakis A, Kostopoulou M, et al. EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Dec 12, 2025, 15:11Webinar on Fertility Preservation in Cancer Care – ESHRE
-
Dec 12, 2025, 14:59Novel Microfluidics Device Enhances Sperm Selection Success – Fertility and Sterility
-
Dec 12, 2025, 14:55Human Embryo Preimplantation Genetic Testing and Phased Validation – Fertility and Sterility
-
Dec 12, 2025, 14:40Unraveling Immune Mechanisms in Reproductive Health – Reproduction and Fertility
-
Dec 12, 2025, 14:30Swarup Chakrabarti: A New Era for IVF Success
-
Dec 12, 2025, 14:25Guidelines Unveiled for Recurrent Pregnancy Loss Management – The ObG Project
-
Dec 12, 2025, 11:31AMWA Advocates for Equitable Care in Endometriosis Treatment – Womb WatchAI
-
Dec 11, 2025, 16:16AI Model Predicts Pregnancy Outcomes Through Endometrial Receptivity Scoring – Future Fertility
-
Dec 11, 2025, 15:55Houssein El Hajj: Training Without Borders: Mobility and Opportunity in Gynaecologic Oncology